Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rexlemestrocel-L

Cell therapy (Stem-cell derived) · developed by Mesoblast

Phase 3 Most advanced trial
MESO Developer
2 Registered trials

What is Rexlemestrocel-L?

Rexlemestrocel-L is an allogeneic cell therapy made of human bone marrow-derived mesenchymal precursor cells, isolated with anti-STRO-3 antibodies, expanded ex vivo and cryopreserved. It is studied in degenerative disc disease and chronic heart failure.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Stem-cell derived)
Therapy area
Musculoskeletal
Developer
Mesoblast, Ltd. (MESO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
4LS0IJZ59V

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06325566 Phase 3 Degenerative Disc Disease Active not recruiting MESO
NCT02032004 Phase 3 Chronic Heart Failure Completed MESO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Degenerative Disc DiseaseChronic Heart Failure

More from Mesoblast

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.

Follow MESO, the company behind Rexlemestrocel-L

See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MESO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.